New combo therapy aims to tackle tough pancreatic tumors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with pathologically proven diagnosis of adenocarcinoma of the pancreas * After chemotherapy, tumor is determined to be either locally advanced or unresectable by hepatobiliary surgeon; or tumor is considered potentially resectable but subject does not proceed with surgical resection for any reason * Have completed first line chemotherapy without progression or non-regional metastases * Tumor is radiographically evident on CT scan after chemotherapy * Tumor is anatomically amenable to SBRT, e.g. does not directly invade the stomach or bowel * Tumor is amenable to intra-tumor injection under endoscopic ultrasound guidance * ECOG performance status 0-2 * Patients with childbearing potential must demonstrate a negative urine or serum pregnancy test * Male or female subjects, aged at least 18 years; Female subjects of childbearing potential may participate if adequate contraception is used during, and for at least the three months after study completion; Male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least the three months after study completion; Adequate contraception is defined as resulting in a failure rate of less than 1% per year * Patient must be able to understand and willingly sign study specific informed consent prior to study entry * Anticipated life expectancy ≥ 12 weeks * Patients aged at least 18 years of age Exclusion Criteria: * Progression of disease or metastatic disease after first line systemic therapy * Prior radiation treatment or surgical resection of any pancreatic malignancy * Inability to tolerate SBRT, Endoscopic ultrasound or IL-12 Injection procedure * Lack of radiographically evident disease after first line chemotherapy * Severe, active comorbidity that shortens the patient's life expectancy to less than 12 weeks * History of past malignancy * Patient who is pregnant and/or breastfeeding * Inability to comply with other required protocol procedures including required biopsies